Menveo (meningococcal group A, C, W-135 and Y conjugate vaccine)
- Region
- 🇪🇺 EU
- Active substance
- meningococcal group A, C, W-135 and Y conjugate vaccine
- Company
- GSK Vaccines S.r.l.
- Status
- Authorised
- Therapeutic area
- Immunization; Meningitis, Meningococcal
- CHMP opinion
- Thu 17 Dec 2009
- EU approval
- Mon 15 Mar 2010
- Application
- EMEA/H/C/001095
- ATC
- J07AH08
- Official record
- www.ema.europa.eu
Indication
Vials Menveo is indicated for active immunisation of children (from two years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease. The use of this vaccine should be in accordance with official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 MenQuadfi Authorised · Sanofi Winthrop Industrie
Follow Menveo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.